quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:41:31·8d
SECFiling
Kymera Therapeutics Inc. logo

SEC Form 144 filed by Kymera Therapeutics Inc.

KYMR· Kymera Therapeutics Inc.
Health Care
Original source

Companies

  • KYMR
    Kymera Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Mar 16UpdateJefferies-
  • Jan 28UpdateBarclays$133.00
  • Jan 6UpdateWolfe Research-
  • Nov 3UpdateGuggenheim$90.00
  • Oct 24UpdateB. Riley Securities$80.00
  • Oct 21UpdateMizuho$81.00

Related

  • PR23h
    Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026
  • SEC1d
    SEC Form 144 filed by Kymera Therapeutics Inc.
  • SEC1d
    SEC Form 144 filed by Kymera Therapeutics Inc.
  • SEC1d
    SEC Form 144 filed by Kymera Therapeutics Inc.
  • INSIDER7d
    SEC Form 4 filed by Goodman Noah
  • INSIDER7d
    SEC Form 4 filed by Chadwick Jeremy G
  • INSIDER7d
    SEC Form 4 filed by Booth Bruce
  • SEC8d
    SEC Form 144 filed by Kymera Therapeutics Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022